; (7) are reconsidered and revised when new evidence emerges; and (8) clearly identify any exceptions to the application of the clinical practice guideline. (b) Required disclosures from eligible professional organizations Any person who is affiliated with an eligible professional organization and who directly participated in the creation of a clinical practice guideline shall disclose any conflicts of interest pertaining to the development of the clinical practice guideline, including any conflict of interest pertaining to any instrument, medicine, drug, or any other substance, device, or means included in the clinical practice guideline. Disclosures to the Secretary by eligible professional organizations shall be made promptly, upon submission of the guidelines, and during every review of the guidelines. Disclosures shall include the following: (1) Scientific methodology and evidence that supports clinical practice guidelines. (2) Outside collaborators. (3) Endorsements. 503. No liability for guideline producers Neither an eligible professional organization nor the participants in its guideline development and approval process, may be held liable for any injury alleged to be caused by adhering to a clinical practice guideline to which they contributed. 504. Internet publication of guidelines The Secretary shall publish on the Internet through the National Guideline Clearinghouse or other appropriate sites or sources, all clinical practice guidelines, including all data and methodology used in the development and selection of the guidelines in compliance with data disclosure standards in the Health Insurance Portability and Accountability Act of 1996 ( Public Law 104–191 ). 505. State flexibility and protection of States’ rights (a) Limitation This Act shall not preempt or supersede any State or Federal law that— (1) imposes procedural or substantive protections for health care providers and health care organizations from liability, loss, or damages greater than such protections provided by this title